0001571049-17-001169.txt : 20170209 0001571049-17-001169.hdr.sgml : 20170209 20170209161102 ACCESSION NUMBER: 0001571049-17-001169 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36745 FILM NUMBER: 17587686 BUSINESS ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631-240-8800 MAIL ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 10-Q 1 t1700067_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36745

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	59-2262718
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

50 Health Sciences Drive
Stony Brook, New York	11790
(Address of principal executive offices)	(Zip Code)

631-240-8800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

¨ Yes x No

At February 1, 2017, the registrant had 26,351,483 shares of common stock outstanding.

Applied DNA Sciences, Inc.

Form 10-Q for the Quarter Ended December 31, 2016

Table of Contents

		Page
PART I - FINANCIAL INFORMATION

Item 1 - Condensed Consolidated Financial Statements (unaudited)		1

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3 - Quantitative and Qualitative Disclosures About Market Risk		20

Item 4 - Controls and Procedures		21

PART II - OTHER INFORMATION

Item 1 – Legal Proceedings		22

Item 1A – Risk Factors		22

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds		22

Item 3 – Defaults Upon Senior Securities		22

Item 4 – Mine Safety Disclosures		22

Item 5 – Other Information		22

Item 6 – Exhibits		23

Part I - Financial Information

Item 1 - Financial Statements.

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31, 2016			September 30, 2016
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	6,701,586		$	4,479,274
Accounts receivable, net of allowance of $23,411 and $32,965 at December 31, 2016 and September 30, 2016, respectively		6,156,173			6,374,895
Inventories		323,324			297,759
Prepaid expenses and other current assets		133,230			200,006
Total current assets		13,314,313			11,351,934

Property, plant and equipment, net of accumulated depreciation of $1,363,789 at December 31, 2016 and $1,263,200 at September 30, 2016		723,790			792,499

Other assets:
Long term accounts receivables		920,000			1,535,000
Deposits		61,626			61,126
Deferred offering costs		-			13,986
Goodwill		285,386			285,386
Intangible assets, net of accumulated amortization of $485,037 and $423,649 at December 31, 2016 and September 30, 2016, respectively		1,464,512			1,525,900

Total Assets	$	16,769,627		$	15,565,831

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable and accrued liabilities	$	2,201,021		$	2,247,341
Deferred revenue		1,791,707			1,837,588
Total current liabilities		3,992,728			4,084,929

Long term accounts payable		127,000			215,500
Long term deferred revenue		468,000			900,000

Total liabilities		4,587,728			5,200,429

Commitments and contingencies

Stockholders’ Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2016 and September 30, 2016		—			—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2016 and September 30, 2016		—			—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2016 and September 30, 2016		—			—
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 26,351,483 and 24,078,756 shares issued and outstanding as of December 31, 2016 and September 30, 2016, respectively		26,351			24,079
Additional paid in capital		239,934,320			234,158,711
Accumulated deficit		(227,778,772	)		(223,817,388	)
Total stockholders’ equity		12,181,899			10,365,402

Total Liabilities and Stockholders’ Equity	$	16,769,627		$	15,565,831

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended December 31,
	2016			2015

Revenues:
Product revenues	$	704,417		$	693,214
Service revenues		198,591			630,900

Total revenues		903,008			1,324,114

Cost of revenues		274,832			184,268

Operating expenses:
Selling, general and administrative		3,900,917			3,169,063
Research and development		518,628			672,965
Depreciation and amortization		161,977			218,346

Total operating expenses		4,581,522			4,060,374

LOSS FROM OPERATIONS		(3,953,346	)		(2,920,528	)

Other income (expense):
Interest income, net		1,331			2,845
Other expense, net		(9,369	)		(8,587	)

Loss before provision for income taxes		(3,961,384	)		(2,926,270	)

Provision for income taxes		—			—

NET LOSS	$	(3,961,384	)	$	(2,926,270	)

Net loss per share-basic and diluted	$	(0.16	)	$	(0.13	)

Weighted average shares outstanding- Basic and diluted		25,427,407			22,542,176

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended December 31,
	2016			2015

Cash flows from operating activities:
Net loss	$	(3,961,384	)	$	(2,926,270	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		161,977			218,346
Stock-based compensation expense		1,458,020			396,991
Common stock issued for consulting services		—			58,120
Provision for bad debts		5,646			10,000
Change in operating assets and liabilities:
Accounts receivable		828,076			(4,480	)
Inventories		(26,065	)		—
Prepaid expenses and other current assets and deposits		66,776			71,896
Accounts payable and accrued liabilities		(124,053	)		(320,825	)
Deferred revenue		(477,881	)		(224,524	)

Net cash used in operating activities		(2,068,888	)		(2,720,746	)

Cash flows used in investing activities:
Purchase of property, plant and equipment		(42,647	)		(51,795	)
Purchase of intangible assets		—			(14,301	)
Net cash used in investing activities		(42,647	)		(66,096	)

Cash flows from financing activities:

Net proceeds from sale of common stock and warrants		4,333,847			7,853,155
Proceeds from the exercise of warrants		—			4,410

Net cash provided by financing activities		4,333,847			7,857,565

Net increase in cash and cash equivalents		2,222,312			5,070,723
Cash and cash equivalents at beginning of period		4,479,274			7,312,184
Cash and cash equivalents at end of period	$	6,701,586		$	12,382,907

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	$	—		$	—
Cash paid during period for income taxes	$	—		$	—

Non-cash investing and financing activities:
Common stock issued upon cashless exercise of options and warrants	$	—		$	49
Reclassification of deferred offering costs to additional paid-in capital	$	13,986		$	—
Property, plant and equipment acquired, and included in accounts payable	$	—		$	40,908
Intangible assets acquired, and included in accounts payable	$	—		$	17,841
Issuance of options to settle accrued liability	$	—		$	42,335

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying condensed consolidated financial statements as of December 31, 2016 and for the three-month periods ended December 31, 2016 and 2015 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three-month period ended December 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2016 and footnotes thereto included in the Annual Report on Form 10-K of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC on December 6, 2016.

The condensed consolidated balance sheet as of September 30, 2016 contained herein has been derived from the audited consolidated financial statements as of September 30, 2016, but does not include all disclosures required by GAAP.

Business and Basis of Presentation

The Company is principally devoted to developing and marketing plant-based or other DNA technology solutions in the United States, Europe and Asia. To date, the Company has had a limited operating history with its current business model, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment and development of a biotechnology company.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation. To facilitate comparison of information across periods, certain reclassifications have been made to prior year amounts to conform to the current year's presentation.

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or market, with cost determined by using the first-in, first-out (FIFO) method.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2016 and September 30, 2016, the Company recorded deferred revenue of $2,259,707 and $2,737,588, respectively.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Revenue Recognition, continued

Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per each contract. The Company did not recognize revenue from these contracts during the three months ended December 31, 2016. The Company recognized revenue of $504,349 from these contract awards during the three month period ended December 31, 2015.

The Company recognizes the revenue under its memorandum of understanding ("MOU") with LD Commodities Cotton LLC ("Dreyfus") when the product has been shipped, as there is no right of return under this arrangement and there is a commitment from their customer to purchase the marked cotton. The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company is the primary obligor and if it has general inventory risk. The Company does not have any general inventory risk and is not the primary obligor as it relates to the marketing portion of the cotton tagging fee. With respect to the Company’s mutual license agreement with Himatsingka America Inc. (formerly known as Divatex Home Fashion, Inc.) (“Himatsingka”), the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that the circumstances as they relate to Himatsingka’s portion of the tagging fee are more consistent with those key indicators that support net revenue reporting. On June 29, 2016, Himatsingka waived its portion of the tagging fee for up to $250,000. In addition, the nature of some of the Company’s cotton contracts includes extended payment terms that will result in a longer collection period and slower cash inflows. Under the Company’s MOU with Dreyfus, as of December 31, 2016 and September 30, 2016 there was $4,775,339 and $4,621,345 included in short term accounts receivable, respectively. As of December 31, 2016 and September 30, 2016 there was $920,000 and $1,535,000 included in long-term accounts receivable, respectively. Also, as of December 31, 2016 and September 30, 2016 there was $2,106,584 and $2,305,000 included in deferred revenue for shipments during the fiscal year ended September 30, 2016. The cotton ginning season in the United States takes place between September and December each year, therefore, revenues from these customer contracts may be seasonal.

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement, and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.

In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three month periods ended December 31, 2016 and 2015, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three month periods ended December 31, 2016 and 2015 are as follows:

	2016		2015

Warrants		9,548,969		7,324,727
Stock options		5,237,478		3,890,420
		14,786,447		11,215,147

Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2016 included an aggregate of 19% and 50% from two customers, respectively. The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2015 included an aggregate of 45%, 17% and 11% from three customers of the Company’s total revenues, respectively. One customer accounted for 80% and 78% of the Company’s total accounts receivable at December 31, 2016 and September 30, 2016, respectively. Another customer accounted for 16% of the Company’s total accounts receivable at December 31, 2016.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The amendments in this update are to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company is currently evaluating the impact of adopting this guidance.

In March 2016, the FASB issued ASU 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting." The objective of this update is to simplify several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)." The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes" ("ASU 2015-17"). This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position. ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016. This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. Early application is permitted as of the beginning of the interim or annual reporting period. The Company expects the impact of the adoption of this pronouncement on its condensed consolidated balance sheet to be a reclassification only, and does not expect the pronouncement to have a significant impact.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out ("LIFO") method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. The Company does not expect the adoption of ASU 2015-11 to have a material effect on its condensed consolidated financial statements.

In August 2014, FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration they expect to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of ASU 2014-09 and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. However, we expect to identify similar performance obligations under ASC 2014-09 as compared with deliverables and separate units of account previously identified. As a result, we expect the timing of our revenue to remain the same.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE B — LIQUIDITY AND MANAGEMENT’S PLAN

The Company has recurring net losses, which have resulted in an accumulated deficit of $227,778,772 as of December 31, 2016. The Company incurred a net loss of $3,961,384 and generated negative operating cash flow of $2,068,888 for the three month period ended December 31, 2016. The Company also had working capital of $9,321,585 and cash and cash equivalents of $6,701,586 as of December 31, 2016. The Company’s current capital resources include cash and cash equivalents, accounts receivable, and inventories. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note E, on November 7, 2016, the Company closed a private placement of common stock and warrants to purchase common stock, for an aggregate gross proceeds of $5 million, before deducting placement agent fees and offering expenses. Total net proceeds were approximately $4.3 million.

The Company expects to finance operations and capital expenditures primarily through cash received from the November 2016 private placement, as well as collection of its current accounts receivables. The Company estimates that it will have sufficient cash and cash equivalents to fund operations for the next twelve months from the balance sheet date.

The Company may require additional funds to expand the marketing and complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses. If revenues are not sufficient to cover the Company's operating expenses, and if the Company is not successful in obtaining necessary additional financing, it will most likely be forced to reduce operations.

NOTE C — INVENTORIES

Inventories consist of the following:

	December 31, 2016		September 30, 2016
	(unaudited)
Raw materials	$	125,039	$	100,420
Finished goods		198,285		197,339
Total	$	323,324	$	297,759

NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are as follows:

	December 31, 2016		September 30, 2016
	(unaudited)
Accounts payable	$	1,657,808	$	1,530,258
Accrued salaries payable		399,024		678,982
Other accrued expenses		144,189		38,101
Total	$	2,201,021	$	2,247,341

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE E — CAPITAL STOCK

On November 2, 2016, the Company entered into a securities purchase agreement with an institutional investor providing for the purchase of $5 million of common stock and warrants at a combined price of $2.20 per share of common stock and warrant (the “Private Placement”). In the Private Placement, the Company sold 2,272,727 shares of its common stock and warrants to purchase 2,272,727 shares of its common stock. The warrants have the same terms as the Company's existing publicly traded warrants (APDNW) with an exercise price of $3.50 per share and an expiration date of November 20, 2019. The offering closed on November 7, 2016.

The Company agreed to file a registration statement providing for the resale of these securities on Form S-3 by December 7, 2016. On December 6, 2016, the Company filed the Form S-3, which was declared effective by the SEC on December 13, 2016. Upon effectiveness of the registration statement, the common stock and warrants issued in the Private Placement became freely tradeable on The NASDAQ Capital Market under the symbols "APDN" and "APDNW", respectively.

The aggregate gross proceeds to the Company from the Private Placement were $5 million before deducting the placement agents' fee and other offering expenses. As a result of the placement agents’ fee and other offering expenses attributable to the Private Placement, the net proceeds were $4,319,861.

In connection with the closing of this Private Placement, as partial compensation, on November 7, 2016, the Company granted warrants to purchase an aggregate of 68,182 shares of its common stock to the Company's placement agents, Maxim Group LLC and Imperial Capital LLC (the “Placement Agent Warrants”) at an exercise price of $2.53 (115% of the public offering price), subject to adjustment as set forth therein (including for stock dividends and splits and certain other distributions and “Fundamental Transactions,” as defined therein). The Placement Agent Warrants will be exercisable beginning six months following the closing date of the Private Placement and terminate at 5:00 P.M. (Eastern Standard Time) on November 7, 2021. In addition, the Placement Agent Warrants provide for cashless exercise, which the Placement Agents may elect if there is no effective registration statement registering the resale of the shares issuable upon exercise of the Placement Agent Warrants. The number of shares of common stock that may be acquired by the Placement Agents upon any exercise of the Placement Agent Warrants (or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise, the total number of shares of common stock then beneficially owned by the Placement Agent and its Affiliates (as defined therein) and any other Persons whose beneficial ownership of common stock would be aggregated with the Placement Agent pursuant to the Exchange Act, does not exceed 9.99% of the total number of issued and outstanding shares of common stock.

NOTE F — STOCK OPTIONS AND WARRANTS

Warrants

During the three months ended December 31, 2016, the Company issued warrants to purchase 2,272,727 shares of its common stock as part of the Private Placement (See Note E). In addition, warrants to purchase an aggregate of 68,182 shares of common stock were issued to the Company's placement agents, Maxim Group LLC and Imperial Capital LLC (See Note E).

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE F — STOCK OPTIONS AND WARRANTS (continued)

Warrants, continued

Transactions involving warrants are summarized as follows:

	Number of Shares		Weighted Average Exercise Price Per Share
Balance at October 1, 2016		7,208,060	$	3.64
Granted		2,340,909		3.47
Exercised		-		-
Cancelled or expired		-		-
Balance at December 31, 2016		9,548,969	$	3.60

Stock Options

In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008, 2012 and 2015, the Board of Directors and holders of a majority of the outstanding shares of common stock present at the annual meetings of stockholders approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,833,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.

The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options. As of December 31, 2016, a total of 275,752 shares have been issued and options to purchase 5,759,601 shares have been granted under the Incentive Plan.

Transactions involving stock options issued to employees and consultants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2016		4,403,234		$	4.08
Granted		837,328			2.07
Exercised		-			-
Cancelled or expired		(3,084	)		(3.07	)
Outstanding at December 31, 2016		5,237,478		$	3.76
Vested at December 31, 2016		3,829,118		$	3.95		$	222,290		4.66
Non-vested at December 31, 2016		1,408,360					$	129,083		7.99

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016

(unaudited)

NOTE F — STOCK OPTIONS AND WARRANTS (continued)

Stock Options, continued

During the three month period ended December 31, 2016, the Company issued an aggregate of 837,328 options to employees, non-employee board of director members, a consultant and members of the strategic advisory board. Included in these grants were 280,000 options granted to executives during the three month period ended December 31, 2016 and 5,000 performance based options granted to a consultant. These performance based options vest when a certain performance condition is met by the consultant.

The fair value of options granted during the three month periods ended December 31, 2016 and 2015 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:

	Three Months Ended December 31, 2016			Three Months Ended December 31, 2015
Stock price	$	2.06		$	3.04
Exercise price	$	2.06		$	3.04
Expected term, years		5.35			6.10
Dividend yield		-	%		-	%
Volatility		112	%		130	%
Risk free rate		2.0	%		1.8	%

The Company recorded $1,458,020 and $396,991 as stock compensation expense for the three month period ended December 31, 2016 and 2015, respectively. Included in this amount is $74,537 for the three month period ended December 31, 2016 for stock option modifications to extend the term of options for certain nonemployee board of director members. As of December 31, 2016, unrecorded compensation cost related to non-vested awards was $3,568,665, which is expected to be recognized over a weighted average period of approximately 3.27 years. The weighted average grant date fair value per share for options granted during the three month periods ended December 31, 2016 and 2015 was $1.68 and $2.71, respectively.

NOTE G — COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expired on May 31, 2016, with the option to extend the lease for up to two additional three-year periods. The Company has exercised its option to extend the lease for one additional three-year period, ending May 31, 2019. The base rent during the additional three-year period is $458,098 per annum. Total rent expense for the three months ended December 31, 2016 and 2015 was $140,397 and $144,716, respectively.

Employment Agreement

The Company has an employment agreement with Dr. James Hayward, its Chief Executive Officer. On July 28, 2016, a new employment agreement was entered into with the Chief Executive Officer effective July 1, 2016. The initial term is from July 1, 2016 through June 30, 2017, with automatic one-year renewal periods. The terms of the agreement are substantially the same as his original employment agreement, except the cash incentive bonus was modified. Under the new agreement, Dr. Hayward will be eligible for a special cash incentive bonus of up to $800,000, $300,000 of which will be payable if and when annual revenue reaches $8 million and $100,000 of which would be payable for each $2 million of annual revenue in excess of $8 million. Dr Hayward's annual salary is $400,000.

Effective May 7, 2016, the Chief Executive Officer's annual salary was voluntarily reduced by $100,000. Accordingly, his current annual base salary as of December 31, 2016 is $300,000.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

NOTE H– GEOGRAPHIC AREA INFORMATION

Net revenues by geographic location of customers are as follows:

Three Months Ended December 31,
	2016		2015
United States	$	588,900	$	1,049,402
Europe		294,333		240,192
Asia and other		19,775		34,520
Total	$	903,008	$	1,324,114

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q (including but not limited to this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are intended to qualify for the “safe harbor” created by those sections. In addition, we may make forward-looking statements in other documents filed with or furnished to the Securities and Exchange Commission (“SEC”), and our management and other representatives may make forward-looking statement orally or in writing to analysts, investors, representatives of the media and others. Forward-looking statements can generally be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as “can”, “may”, “could”, “should”, “assume”, “forecasts”, “believe”, “designated to”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential”, “position”, “predicts”, “strategy”, “guidance”, “intend”, “budget”, “seek”, “project” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

●

discuss our future expectations;

●

contain projections of our future results of operations or of our financial condition; and

●

state other “forward-looking” information.

We believe it is important to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a variety of factors and risks, including, but not limited to, those set forth in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2016, and the following factors and risks:

our short operating history, with our current business model and lack of significant revenues;

our history of net losses, which may continue, and our potential inability to achieve profitability;

the possibility that we may require additional financing, which may involve the issuance of additional shares of common stock or securities exercisable for common stock and dilute the percentage of ownership held by our current stockholders;

difficulty in obtaining, or inability to obtain, additional financing if such financing becomes necessary.;

volatility in the price and/or trading volume of our common stock;

future short selling and/or manipulation of the price of our common stock;

our inability to implement our short and long-term strategies;

competition from products and services provided by other companies;

potential difficulties and failures in manufacturing our products;

loss of strategic relationships;

dependence on a limited number of key customers;

lack of acceptance of our products and services by potential customers;

potential failure to introduce new products and services;

difficulty or failure in expanding/ and or maintaining our sales, marketing and support organizations and our distribution arrangements necessary to enable us to reach our goals with respect to increasing market acceptance of our products and services;

seasonality in revenues related to our cotton customer contracts;

inability to continue to retain the services of Dr. Hayward, our Chief Executive Office;

inability to compete effectively in the industries in which we operate;

lack of success in our research and development efforts for new products;

failure to manage our growth in operations and acquisitions of new technologies and businesses;

inability to protect our intellectual property rights;

intellectual property litigation against us or other legal actions or proceedings in which we may become involved;

unauthorized disclosure of sensitive or confidential data (including customer data) and cybersecurity breaches; and

adverse changes in worldwide or domestic economic, political or business conditions.

All forward-looking statements and risk factors included in this Quarterly Report are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law. Assumptions relating to the forward-looking statements included in this Quarterly Report involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control.

Any of the assumptions underlying the forward-looking statements contained in this Quarterly Report could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized and we caution you against relying on any of the forward-looking statements contained herein.

Note

Our trademarks in the United States include SigNature^®DNA, SigNature^® T DNA, fiberTyping^®, DNAnet^®, digitalDNA^®, SigNify™, BackTrac™ and Beacon^TM. All trademarks, service marks and trade names included or incorporated by reference in this Quarterly Report on 10-Q are the property of their respective owners, including, without limitation, SmokeCloak^®, a mark owned by MSS Professional A/S and/or its affiliates, and PimaCott^®, a mark owned by Himatsingka America (formerly known as Divatex Home Fashion, Inc.) and/or its affiliates.

Introduction

Using biotechnology as a forensic foundation, we create unique security solutions addressing the challenges of modern commerce. Whether for supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success. With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our plant-based or other DNA technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction (“PCR”).

SigNature DNA, the core of our technology platform, is nature’s ultimate means of authentication and supply chain security. Founded on plant-based DNA, our precision-engineered marks have not and, we believe, cannot be broken. The conventional process used to sequence (“decode”) native DNA is not possible with the engineered mark. Additional layers of protection and complexity are added to the mark in a proprietary manner. SigNature DNA can resist wash off, even in aggressive industrial treatment baths. SigNature DNA has proven highly resistant to UV radiation, heat, cold, vibration, abrasion and other extreme environments and conditions. We work closely with our customers to develop a solution that will be optimized to their specifications to deliver maximum impact. Our products and technology are protected by a robust portfolio of patents and trademarks.

Using our products and technology, manufacturers, brands, and other stakeholders can ensure authenticity and protect against diversion throughout a product’s journey from manufacturer to use.

Signature DNA Markers

SigNature DNA. SigNature DNA is our patented platform ingredient, at the core of all our security solutions. It provides forensic power and protection for a wide array of applications. Highly secure, robust and durable, SigNature DNA markers are an ingredient that can be used to fortify brand protection efforts; strengthen supply chain security; and mark, track and convict criminals. Custom DNA sequences can be embedded into a wide range of host carriers including ink, varnish, thread, laminates and metal coatings. SigNature DNA markers are resistant to heat, cold, vibration, abrasion, organic solvents, chemicals, UV radiation and other extreme environmental conditions, and so can be identified for numerous years after being embedded directly, or into media applied or attached to the item to be marked. Each individual marker is recorded and stored in a secure database so that we can later detect it using a simple spot test, or the marks can be forensically analyzed to obtain definitive proof of the presence or absence of a specific type of SigNature DNA marker (e.g., one designed to mark a particular product). Our in-lab forensic testing for authenticity results in an expert witness Certificate of DNA Authentication (CODA). Because DNA is one of the most dense information carriers known, only minute quantities of SigNature DNA are necessary for successful analysis and authentication. As a result, SigNature DNA can fold seamlessly into production and logistics workflows.

SigNature DNA has been subjected to rigorous testing by the Idaho National Laboratory, a U.S. National Laboratory, by CALCE (the Center for Advanced Life Cycle Engineering), the largest electronic products and systems research center focused on electronics reliability, and by verified procedures in our laboratories. The forensic marker has passed all tests across a broad spectrum of materials and has met key military stability standards. SigNature DNA has passed a strenuous “red-team” vetting on behalf of the U.S. Defense Logistics Agency.

Hundreds of millions of SigNature DNA markers now exist on items ranging from consumer product packaging to microcircuits; to our knowledge, none has ever been copied.

SigNature T DNA and fiberTyping

SigNature T. SigNature T DNA is a unique patent-pending tagging and authentication system specifically designed for textiles and apparel. Specially engineered to adhere tenaciously to any kind of textile substrate, including natural and synthetic fibers, SigNature T DNA markers are resistant to standard textile production conditions, and cannot be copied. The result: an enduring forensic identity marker that remains present from the fiber stage through to the finished product.

This technology allows for better quality control and assurance at any point in the supply chain. Signature T DNA markers are used for brand protection efforts and raw material, source compliance programs. For example, cotton fibers can be tagged at source, verified as “American grown” and then traced through every step of the supply chain.

Our patented genotyping platform, known as “fiberTyping®”, described below, complements tagging with SigNature T plant-based DNA. fiberTyping is employed to identify the genus and species of the fibers before or after they are tagged with SigNature T DNA. fiberTyping cannot be used to track a specific cotton batch through the supply chain, a function which can only be accomplished by our Signature T DNA system.

fiberTyping. fiberTyping is not a marker, but a test of native cotton fiber, which gives a clear result that determines whether the intended cotton DNA is present in your fiber, yarn or fabric. Samples from the primary material are sent to our forensic labs for DNA analysis and authentication. Cotton classification and the authentication of cotton geographic origin are issues of global significance, important to brand owners and to governments that must regulate the international cotton trade. The use of DNA to identify the cotton fiber content of finished textiles is a significant opportunity for license holders to control their brand and for governments to improve their ability to enforce compliance with trade agreements between nations.

In addition to the global cotton trade, the potential markets for genotyping include biotherapeutics, nutraceuticals, natural foods, wines and fermented alcohols and other natural textiles.

We believe that our DNA extraction protocol and methodologies are more effective than existing forensic systems. We believe that the combination of our SigNatureT DNA and fiberTyping solutions cover the forensic authentication market for textiles and secure systems and protocols developed may be applicable to multiple industry verticals, and can mark and authenticate products at every stage of their life cycle, from beginning to end.

DNAnet and Backtrac

Recognizing that DNA-based evidence is the cornerstone of modern-era law enforcement, we have developed what we believe to be the ultimate crime fighting tools – currently being used in home asset and vehicle marking, as well as commercial applications.

DNAnet. DNAnet, a DNA marker can be used to definitively link evidence and offenders to specific crime scenes. As the crime is investigated, the fluorescing DNA marker can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict.

Backtrac. Backtrac(TM) is a long lasting tagging solution containing molecular signature that can help return stolen or lost property to its rightful owner.

Beacon

Beacon. Beacon locked optical markers deliver secure real-time inspection capabilities. A unique encrypted mechanism (patent-pending) creates a protected, covert screening tool that can be easily adapted to packaging, security labels and high–value assets through inks, varnishes and coatings. When Beacon locked optical markers are combined with SigNature DNA markers, a strong and flexible end-to-end security solution is created where authenticity and provenance can be determined with confidence.

SigNify

SigNify. Developing a secure method for real-time, in-field screening of DNA-marked items has long been a priority for us. We believe that standard fluorophores, up-converting phosphors, holograms and other more-traditional screening tools provide little to no defense against counterfeiting. We believe that secure in-field inspection, backed with forensic-level DNA authentication is the key to maintaining a well-defended supply chain or asset management program.

The SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA in the field– DNA becomes a true, front-line solution for supply chain integrity.

Information Technology Systems

digitalDNA. digitalDNA is a software platform that enables customers to manage the security of company-marked goods from point of marking to point of authentication or validation to end of life. The base platform is configurable to customer requirements which differ by vertical market, company business process and IT environment. Basic functions offered include DNA inventory management, program training and communications, a database of marked items information, associated documents and images, chain of custody and location tracking, sample authentication processing and CODA downloads, and other administrative functions. Architected for either cloud or local operation, the system supports mobile data capture using bar codes or other technologies. Of special note is the power of embedding our proprietary DNA into tag ink or substrate as the forensic backstop for tags which can be easily copied. The system is architected as the controller and repository for other validation and authentication devices such as our SigNify DNA Readers, Multi-Mode Reader (prototype), DNA Transfer Systems, and other third party devices and is designed to share data with third party applications through standard interfaces.

DNA Transfer Systems. Our DNA Transfer Systems are developed for DNA marking applications which are high volume with a need for monitoring and control. They are computer based, fully automated, offer remote internet access for real-time monitoring and can be configured for application-specific alerts and reporting online. They are used to mark cotton at all seven U.S. cotton gins in the 2016 season.

Large-scale production of specific DNA sequences using PCR.

Large-scale production of specific DNA sequences using PCR. Our patented Triathlon™ PCR systems allow for the large-scale production of specific DNA sequences. The systems are self-contained and modular, can work together in mass production or can be used individually throughout the world, offering the advantage of delivering DNA locally and securely. These DNA sequences are being used by customers as a diagnostic and reagent and provide us the opportunity to cross-sell our DNA-based supply chain security solutions. A new capacity for us will be the ability to manufacture longer DNA sequences valuable in gene therapy, DNA vaccines and diagnostics. These types of DNA are distinct from our DNA security markers and represent a potential new entry into medical markets, where we believe there are opportunities for our broader platform.

Plan of Operations

General

To date, the substantial portion of our revenues have been generated from sales of our SigNature DNA and SigNature T DNA, our principal supply chain security and product authentication solutions. We expect to continue to grow revenues from sales of our SigNature DNA, Signature T DNA, DNAnet, BackTrac, digitalDNA, Beacon and SigNify offerings as well as from large scale production of specific DNA sequences using PCR as we work with companies and governments to secure supply chains and restore confidence to products and product labeling throughout the world. We have continued to incur expenses in expanding our business and increasing our personnel to meet current and anticipated future demand. We have limited sources of liquidity. Our products and services are offered in the United States, Europe and Asia. At the present time, we are focusing our efforts on textile and apparel, microcircuits and other electronics, cash-in-transit, consumer asset marking, printing and packaging businesses and diagnostics and reagents. In the future, we plan to expand our focus to include pharmaceuticals, consumer products, food and beverage, industrial materials, and agrochemicals. The cotton ginning season in the United States takes place between September and December each year, therefore, revenues from our cotton customer contracts may be seasonal, which may cause our operating results to fluctuate significantly quarterly and annually. For a discussion on seasonality see Note A to the accompanying unaudited condensed consolidated financial statements.

Critical Accounting Policies

See Note A to the accompanying unaudited condensed consolidated financial statements for our critical accounting policies.

Comparison of Results of Operations for the Three Month Periods Ended December 31, 2016 and 2015

Revenues

Product revenues

For the three month periods ended December 31, 2016 and 2015, we generated $704,417 and $693,214 in revenues from product sales, respectively. Product revenue remained flat with a small increase of $11,203 or 2% for the three month period ended December 31, 2016 as compared to the three month period ended December 31, 2015. Although product revenues remained flat, there were fluctuations in the types of product revenues during the periods. Decreases in DNA production of $241,000, print of $51,000 and cash and valuables in transit of $30,000 were offset by increases in textiles of $251,000 and consumer asset marking of $72,000.

Service revenues

For the three month periods ended December 31, 2016 and 2015, we generated $198,591 and $630,900 in revenues from sales of services, respectively. Service revenues include our pilot projects and any research and/or development contracts, as well as fiberTyping and authentication services. The decrease in service revenues of $432,309 or 69% for the three month period ended December 31, 2016 as compared to the three month period ended December 31, 2015 is attributable to a decrease in revenue from the two government contract awards of approximately $504,000, of which one expired on July 14, 2016 and the other one in August 2016, offset by an increase in a pilot study for an industrial materials customer of $45,000.

Costs and Expenses

Cost of Revenues

Cost of revenues expense for the three month period ended December 31, 2016 increased by $90,564 or 49% from $184,268 for the three month period ended December 31, 2015 to $274,832 for the three month period ended December 31, 2016. Cost of revenues as a percentage of product revenues was 39% and 27% for the three month periods ended December 31, 2016 and 2015, respectively. This increase in cost of revenues as a percentage of product revenues is due to lower sales to the DNA production industry and an increase in consumer asset marking sales, which have lower gross margin. The increase during the three month period ended December 31, 2016 is also due to the deployment and installation of cotton DNA transfer devices into the field.

Selling, General and Administrative

Selling, general and administrative expenses for the three month period ended December 31, 2016 increased by $731,854 or 23% from $3,169,063 for the three month period ended December 31, 2015 to $3,900,917 for the three month period ended December 31, 2016. The increase is attributable to an increase in stock based compensation expense of $1,061,029, primarily associated with stock option grants during the three months ended December 31, 2016, which vested immediately, whereas the grants during the three month period ended December 31, 2015 have a four year vesting period. This increase was offset by a decrease of $166,000 in legal fees and $130,000 in accounting costs primarily associated with the Company’s audit of Vandalia Research, Inc. ("Vandalia") during the three months ended December 31, 2015.

Research and Development

Research and development expenses decreased to $518,628 for the three month period ended December 31, 2016 from $672,965 for the three month period ended December 31, 2015, a decrease of $154,337 or 23%. This decrease is primarily due to decreased development costs incurred in relation to the two government development contract awards as well as costs related to the cooperative research and development agreement with the United States Department of Agriculture (“USDA”) for enhanced cotton genotyping, all of which expired during fiscal 2016.

Depreciation and Amortization

In the three month period ended December 31, 2016, depreciation and amortization decreased by $56,369 or 26% from $218,346 for the three month period ended December 31, 2015 to $161,977 for the three month period ended December 31, 2016. This decrease is attributable to $69,000 of amortized customer purchase orders acquired from Vandalia and fulfilled by the Company during the three month period ended December 31, 2015, offset by depreciation for fixed assets purchased during fiscal 2016.

Other income (expense)

In the three month period ended December 31, 2016, total other income (expense) increased by $782 from expense of $8,587 for the three month period ended December 31, 2015 to expense of $9,369 for the three month period ended December 31, 2016.

Net Loss

Net loss increased by $1,035,114 or 35% from a loss of $2,926,270 for the three months ended December 31, 2015 to a loss of $3,961,384 for the three months ended December 31, 2016, due to the factors noted above.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of December 31, 2016, we had working capital of $9,321,585. For the three month period ended December 31, 2016, we generated a net cash flow deficit from operating activities of $2,068,888 consisting primarily of our loss of $3,961,384 net with non-cash adjustments of $161,977 in depreciation and amortization charges, $1,458,020 for stock-based compensation, and $5,646 in provision for bad debt expense. Additionally, we had a net decrease in operating assets of $868,787 and a net decrease in operating liabilities of $601,934. Cash used in investing activities was $42,647 for the purchase of property, plant and equipment. Cash provided by financing activities was $4,333,847 consisting primarily of net proceeds from the sale of common stock in the November 2016 private placement of common stock and warrants.

At December 31, 2016, there was approximately $920,000 included in long-term accounts receivable relating to a customer from the cotton industry that purchased SigNature T DNA to secure its cotton supply chain. The nature of this contract includes extended payment terms that will result in a longer collection period and slower cash inflows, which will affect our liquidity and capital resources.

We have recurring net losses, which have resulted in an accumulated deficit of $227,778,772 as of December 31, 2016. We have incurred a net loss of $3,961,384, for the three month period ended December 31, 2016. At December 31, 2016 we had cash and cash equivalents of $6,701,586. Our current capital resources include cash and cash equivalents, accounts receivable, and inventories. Historically, we have financed our operations principally from the sale of equity securities. As disclosed in Note E, to the accompanying unaudited condensed consolidated financial statements, during the three month period ended December 31, 2016, we closed on a private placement of common stock and warrants to purchase common stock, for aggregate gross proceeds of $5 million, before deducting placement agent fees and offering expenses.

We expect to finance operations and capital expenditures primarily through the cash received from the November 2016 private placement as well as collection of our current accounts receivables. We estimate that we will have sufficient cash and cash equivalents to fund operations for the next twelve months from the balance sheet date.

We may require additional funds to expand the marketing and complete the continued development of our products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover our operating expenses. If revenues are not sufficient to cover our operating expenses, and if we are not successful in obtaining the necessary additional financing, we will most likely be forced to reduce operations.

We expect capital expenditures to be less than $150,000 in fiscal 2017. Our primary investments are expected to be in laboratory equipment to support prototyping, manufacturing, our authentication services, and outside services for our detector and reader development.

All of the real property used in our business is leased under operating lease agreements.

On December 3, 2015, we exercised our option to extend the lease for our corporate headquarters in Stony Brook, New York for one additional three-year period. The additional three year term commenced June 1, 2016 and will end May 31, 2019.

Subsequent Events

Not applicable.

Product Research and Development

We anticipate spending approximately $2,750,000 for product research and development activities during the next twelve months.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk.

Information requested by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.

Item 4. — Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2016, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended December 31, 2016, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II — Other Information

Item 1. — Legal Proceedings.

None.

Item 1A. — Risk Factors.

You should carefully consider the risks and uncertainties described under the caption “Forward-Looking Statements” in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of this Quarterly Report and in our other filings with the SEC, including our Annual Report on Form 10-K for the year ended September 30, 2016, and our subsequent filings. The risks and uncertainties described in this Quarterly Report and in our other filings with the SEC are not the only ones facing us. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect us. If any of these risks actually materialize, our business, financial position, results of operations and cash flows could be materially adversely impacted. In that event, the market price of our common stock could decline and you may lose all or part of your investment. As further described under the caption “Forward-Looking Statements” in Part I, Item 2, this Quarterly Report also contains forward-looking statements that involve additional risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements due to the factors and risks described above or other factors.

During the fiscal quarter ended December 31, 2016, there have been no material changes in our risk factors previously disclosed under Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2016.

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds.

See our Current Report on Form 8-K filed on November 3, 2016.

Item 3. — Defaults Upon Senior Securities.

None.

Item 4. — Mine Safety Disclosures.

None.

Item 5. — Other Information.

None.

Item 6. — Exhibits.

31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

32.1**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

101 INS*	XBRL Instance Document

101 SCH*	XBRL Taxonomy Extension Schema Document

101 CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101 LAB*	XBRL Extension Label Linkbase Document

101 PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

+ Management contract or compensatory plan or arrangement.

* Filed herewith.

** Furnished herewith.

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Applied DNA Sciences, Inc.

Dated: February 9, 2017	/s/ JAMES A. HAYWARD
	James A. Hayward, Ph. D.
	Chief Executive Officer
	(Duly authorized officer and principal executive officer)

	/s/ BETH JANTZEN
Dated: February 9, 2017	Beth Jantzen, CPA
	Chief Financial Officer
	(Duly authorized officer and
	principal financial and accounting officer)

EX-31.1 2 t1700067_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, James A. Hayward, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 9, 2017

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.

EX-31.2 3 t1700067_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Beth Jantzen, certify that:

I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 9, 2017

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.

EX-32.1 4 t1700067_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, James A. Hayward, Chief Executive Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2016 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●

the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

●

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.
		Dated: February 9, 2017

EX-32.2 5 t1700067_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Beth Jantzen, Chief Financial Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2016 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●

the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

●

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.
		Dated: February 9, 2017

EX-101.INS 6 apdn-20161231.xml XBRL INSTANCE FILE 0000744452 2013-06-01 2013-06-15 0000744452 2015-10-01 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:TwoCustomersConcentrationRiskMember 2015-10-01 2015-12-31 0000744452 us-gaap:WarrantMember 2015-10-01 2015-12-31 0000744452 us-gaap:EmployeeStockOptionMember 2015-10-01 2015-12-31 0000744452 country:US 2015-10-01 2015-12-31 0000744452 us-gaap:EuropeMember 2015-10-01 2015-12-31 0000744452 apdn:AsiaAndOtherMember 2015-10-01 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:ThreeCustomersConcentrationRiskMember 2015-10-01 2015-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:OneCustomersMember 2015-10-01 2015-12-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2016-05-07 0000744452 apdn:HimatsingkaAmericaIncMember 2016-06-01 2016-06-29 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:NewEmploymentAgreementMember 2016-07-28 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:NewEmploymentAgreementMember 2016-07-01 2016-07-28 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:OneCustomersMember 2015-10-01 2016-09-30 0000744452 2016-09-30 0000744452 us-gaap:SeriesAPreferredStockMember 2016-09-30 0000744452 us-gaap:SeriesBPreferredStockMember 2016-09-30 0000744452 apdn:SecuritiesPurchaseAgreementMember 2016-11-02 0000744452 us-gaap:PrivatePlacementMember 2016-11-02 0000744452 apdn:SecuritiesPurchaseAgreementMember 2016-11-01 2016-11-02 0000744452 us-gaap:PrivatePlacementMember 2016-11-01 2016-11-02 0000744452 us-gaap:PrivatePlacementMember 2016-11-07 0000744452 2016-11-03 2016-11-07 0000744452 us-gaap:PrivatePlacementMember 2016-11-03 2016-11-07 0000744452 2016-10-01 2016-12-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2016-10-01 2016-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:TwoCustomersConcentrationRiskMember 2016-10-01 2016-12-31 0000744452 us-gaap:WarrantMember 2016-10-01 2016-12-31 0000744452 us-gaap:EmployeeStockOptionMember 2016-10-01 2016-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:TwoCustomersConcentrationRiskMember 2016-10-01 2016-12-31 0000744452 us-gaap:PerformanceSharesMember 2016-10-01 2016-12-31 0000744452 apdn:EmployeesConsultantsAndNonEmployeeBoardOfDirectorMembersMember us-gaap:EmployeeStockOptionMember 2016-10-01 2016-12-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2016-10-01 2016-12-31 0000744452 us-gaap:ExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2016-10-01 2016-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:OneCustomersMember 2016-10-01 2016-12-31 0000744452 country:US 2016-10-01 2016-12-31 0000744452 us-gaap:EuropeMember 2016-10-01 2016-12-31 0000744452 apdn:AsiaAndOtherMember 2016-10-01 2016-12-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:OneCustomersMember 2016-10-01 2016-12-31 0000744452 2016-12-31 0000744452 us-gaap:SeriesAPreferredStockMember 2016-12-31 0000744452 us-gaap:SeriesBPreferredStockMember 2016-12-31 0000744452 us-gaap:PrivatePlacementMember 2016-12-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2016-12-31 0000744452 2017-02-01 0000744452 2015-09-30 0000744452 2015-12-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2016-09-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure apdn:Customer utr:sqft APPLIED DNA SCIENCES INC 0000744452 apdn --09-30 Smaller Reporting Company 26351483 10-Q 2016-12-31 false 2017 Q1

4479274

6701586

7312184

12382907

6374895

6156173

297759

323324

200006

133230

11351934

13314313

792499

723790

1535000

920000

61126

61626

285386

1525900

1464512

15565831

16769627

2247341

2201021

1837588

1791707

4084929

3992728

215500 127000

5200429

4587728

24079

26351

234158711

239934320

-223817388

-227778772

10365402

12181899

15565831

16769627

32965

23411

1263200

1363789

423649

485037

0.001

10000000

0.001

500000000

24078756

26351483

24078756

26351483

1324114

1049402

240192

34520

903008

588900

294333

19775

184268

274832

3169063

3900917

672965

518628

218346

161977

4060374

4581522

-2920528

-3953346

2845

1331

-8587

-9369

-2926270

-3961384

-2926270

-3961384

-0.13

-0.16

22542176

25427407

218346

161977

396991

1458020

58120

10000

5646

4480

-828076

26065

-71896

-66776

-320825

-124053

-224524

-477881

-2720746

-2068888

51795

42647

14301

-66096

-42647

7853155 4333847

4410

7857565

4333847

5070723

2222312

40908 17841 13986

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE A — SUMMARY OF ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>General</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying condensed consolidated financial statements as of December 31, 2016 and for the three-month periods ended December 31, 2016 and 2015 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three-month period ended December 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2016 and footnotes thereto included in the Annual Report on Form 10-K of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC on December 6, 2016.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The condensed consolidated balance sheet as of September 30, 2016 contained herein has been derived from the audited consolidated financial statements as of September 30, 2016, but does not include all disclosures required by GAAP.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Business and Basis of Presentation</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is principally devoted to developing and marketing plant-based or other DNA technology solutions in the United States, Europe and Asia. To date, the Company has had a limited operating history with its current business model, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment and development of a biotechnology company.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.  To facilitate comparison of information across periods, certain reclassifications have been made to prior year amounts to conform to the current year's presentation.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Inventories</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or market, with cost determined by using the first-in, first-out (FIFO) method.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Revenue Recognition</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2016 and September 30, 2016, the Company recorded deferred revenue of $2,259,707 and $2,737,588, respectively.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The applicable revenue recognition criteria are then applied to each of the units.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per each contract. The Company did not recognize revenue from these contracts during the three months ended December 31, 2016. The Company recognized revenue of $504,349 from these contract awards during the three month period ended December 31, 2015.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognizes the revenue under its memorandum of understanding ("MOU") with LD Commodities Cotton LLC ("Dreyfus") when the product has been shipped, as there is no right of return under this arrangement and there is a commitment from their customer to purchase the marked cotton. The Company has evaluated the other indicators of gross and net revenue recognition, including whether or not the Company is the primary obligor and if it has general inventory risk. The Company does not have any general inventory risk and is not the primary obligor as it relates to the marketing portion of the cotton tagging fee. With respect to the Company’s mutual license agreement with Himatsingka America Inc. (formerly known as Divatex Home Fashion, Inc.) (“Himatsingka”), the Company has carefully evaluated all of the key gross and net revenue recognition indicators and has concluded that the circumstances as they relate to Himatsingka’s portion of the tagging fee are more consistent with those key indicators that support net revenue reporting. On June 29, 2016, Himatsingka waived its portion of the tagging fee for up to $250,000. In addition, the nature of some of the Company’s cotton contracts includes extended payment terms that will result in a longer collection period and slower cash inflows. Under the Company’s MOU with Dreyfus, as of December 31, 2016 and September 30, 2016 there was $4,775,339 and $4,621,345 included in short term accounts receivable, respectively. As of December 31, 2016 and September 30, 2016 there was $920,000 and $1,535,000 included in long-term accounts receivable, respectively. Also, as of December 31, 2016 and September 30, 2016 there was $2,106,584 and $2,305,000 included in deferred revenue for shipments during the fiscal year ended September 30, 2016. The cotton ginning season in the United States takes place between September and December each year, therefore, revenues from these customer contracts may be seasonal.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Use of Estimates</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Income Taxes</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement, and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Net Loss Per Share</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the three month periods ended December 31, 2016 and 2015, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three month periods ended December 31, 2016 and 2015 are as follows: </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1533.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2016</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1135.56px;">Warrants</td> <td style="width: 15.55px;"> </td> <td style="width: 15.55px; text-align: left;"> </td> <td style="width: 154.44px; text-align: right;">9,548,969</td> <td style="width: 15.55px; text-align: left;"> </td> <td style="width: 14.44px;"> </td> <td style="width: 14.44px; text-align: left;"> </td> <td style="width: 153.33px; text-align: right;">7,324,727</td> <td style="width: 14.44px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Stock options</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">5,237,478</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3,890,420</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px; padding-left: 2in;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">14,786,447</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">11,215,147</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Stock-Based Compensation</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Concentrations</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2016 included an aggregate of 19% and 50% from two customers, respectively. The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2015 included an aggregate of 45%, 17% and 11% from three customers of the Company’s total revenues, respectively. One customer accounted for 80% and 78% of the Company’s total accounts receivable at December 31, 2016 and September 30, 2016, respectively. Another customer accounted for 16% of the Company’s total accounts receivable at December 31, 2016.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The amendments in this update are to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company is currently evaluating the impact of adopting this guidance.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2016, the FASB issued ASU 2016-09, "Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting." The objective of this update is to simplify several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)." The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes" ("ASU 2015-17").   This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company expects the impact of the adoption of this pronouncement on its condensed consolidated balance sheet to be a reclassification only, and does not expect the pronouncement to have a significant impact.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out ("LIFO") method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. The Company does not expect the adoption of ASU 2015-11 to have a material effect on its condensed consolidated financial statements.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, <font style="background-color: white;">FASB</font> issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b> </b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration they expect to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of ASU 2014-09 and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. However, we expect to identify similar performance obligations under ASC 2014-09 as compared with deliverables and separate units of account previously identified. As a result, we expect the timing of our revenue to remain the same.</p>

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>NOTE F — STOCK OPTIONS AND WARRANTS</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Warrants</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the three months ended December 31, 2016, the Company issued warrants to purchase 2,272,727 shares of its common stock as part of the Private Placement (See Note E). In addition, warrants to purchase an aggregate of 68,182 shares of common stock were issued to the Company's placement agents, Maxim Group LLC and Imperial Capital LLC (See Note E).</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.</p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">  </div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Transactions involving warrants are summarized as follows:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of <br />Shares</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted <br />Average <br />Exercise <br />Price Per <br />Share</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1020px;">Balance at October 1, 2016</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 138px; text-align: right;">7,208,060</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 137px; text-align: right;">3.64</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,340,909</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.47</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px;">Balance at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,548,969</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">3.60</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><u>Stock Options</u></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008, 2012 and 2015, the Board of Directors and holders of a majority of the outstanding shares of common stock present at the annual meetings of stockholders approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,833,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options. As of December 31, 2016, a total of 275,752 shares have been issued and options to purchase 5,759,601 shares have been granted under the Incentive Plan.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Transactions involving stock options issued to employees and consultants are summarized as follows:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of <br />Shares</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted <br />Average <br />Exercise <br />Price Per <br />Share</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate <br />Intrinsic <br />Value</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Contractual Life (Years)</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 715px;">Outstanding at October 1, 2016</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 151px; text-align: right;">4,403,234</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 151px; text-align: right;">4.08</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 152px; text-align: right;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 21px; text-align: left;"> </td> <td style="width: 212px; text-align: center;"> </td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">837,328</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.07</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(3,084</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(3.07</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: right; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: center; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Outstanding at December 31, 2016</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,237,478</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.76</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4px;">Vested at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">3,829,118</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;">$</td> <td style="text-align: right; padding-bottom: 4px;">3.95</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">222,290</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;">4.66</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px;">Non-vested at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,408,360</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: right; padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">129,083</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;">7.99</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </div> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the three month period ended December 31, 2016, the Company issued an aggregate of 837,328 options to employees, non-employee board of director members, a consultant and members of the strategic advisory board. Included in these grants were 280,000 options granted to executives during the three month period ended December 31, 2016 and 5,000 performance based options granted to a consultant. These performance based options vest when a certain performance condition is met by the consultant.</div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The fair value of options granted during the three month periods ended December 31, 2016 and 2015 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:</div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Three <br />Months <br />Ended <br />December 31, 2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Three <br />Months <br />Ended <br />December 31, 2015</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 985px;">Stock price</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 133px; text-align: right;">2.06</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 133px; text-align: right;">3.04</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">2.06</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.04</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-align: left;">Expected term, years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5.35</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6.10</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Risk free rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.8</td> <td style="text-align: left;">%</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"> </p> <div style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company recorded $1,458,020 and $396,991 as stock compensation expense for the three month period ended December 31, 2016 and 2015, respectively. Included in this amount is $74,537 for the three month period ended December 31, 2016 for stock option modifications to extend the term of options for certain nonemployee board of director members. As of December 31, 2016, unrecorded compensation cost related to non-vested awards was $3,568,665, which is expected to be recognized over a weighted average period of approximately 3.27 years. The weighted average grant date fair value per share for options granted during the three month periods ended December 31, 2016 and 2015 was $1.68 and $2.71, respectively.</div> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2016</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1020px;">Warrants</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 138px; text-align: right;">9,548,969</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 137px; text-align: right;">7,324,727</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Stock options</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">5,237,478</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3,890,420</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-indent: -2in; padding-bottom: 4px; padding-left: 2in;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">14,786,447</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">11,215,147</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">December 31,<br />2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">September 30, <br />2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: right;" colspan="2">(unaudited)</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1020px; text-align: left;">Raw materials</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 138px; text-align: right;">125,039</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 137px; text-align: right;">100,420</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Finished goods</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">198,285</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">197,339</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">323,324</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">297,759</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">December 31,<br />2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">September 30, <br />2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: right;" colspan="2">(unaudited)</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1020px; text-align: left;">Accounts payable</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 138px; text-align: right;">1,657,808</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 137px; text-align: right;">1,530,258</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Accrued salaries payable</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">399,024</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">678,982</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-align: left; padding-bottom: 2px;">Other accrued expenses</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">144,189</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">38,101</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,201,021</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,247,341</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of <br />Shares</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted <br />Average <br />Exercise <br />Price Per <br />Share</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 1020px;">Balance at October 1, 2016</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 138px; text-align: right;">7,208,060</td> <td style="width: 14px; text-align: left;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 137px; text-align: right;">3.64</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,340,909</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.47</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px;">Balance at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,548,969</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">3.60</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

<div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of <br />Shares</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted <br />Average <br />Exercise <br />Price Per <br />Share</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate <br />Intrinsic <br />Value</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average Contractual Life (Years)</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 715px;">Outstanding at October 1, 2016</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 151px; text-align: right;">4,403,234</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 151px; text-align: right;">4.08</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 152px; text-align: right;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 21px; text-align: left;"> </td> <td style="width: 212px; text-align: center;"> </td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">837,328</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.07</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Cancelled or expired</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(3,084</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(3.07</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: right; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="text-align: center; padding-bottom: 2px;"> </td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Outstanding at December 31, 2016</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,237,478</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.76</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4px;">Vested at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">3,829,118</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;">$</td> <td style="text-align: right; padding-bottom: 4px;">3.95</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">222,290</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;">4.66</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="padding-bottom: 4px;">Non-vested at December 31, 2016</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,408,360</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: right; padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">129,083</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="text-align: center; padding-bottom: 4px;">7.99</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div> <div> </div>

<div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Three <br />Months <br />Ended <br />December 31, 2016</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Three <br />Months <br />Ended <br />December 31, 2015</td> <td style="padding-bottom: 2px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 985px;">Stock price</td> <td style="width: 14px;"> </td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 133px; text-align: right;">2.06</td> <td style="width: 13px; text-align: left;"> </td> <td style="width: 13px;"> </td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 133px; text-align: right;">3.04</td> <td style="width: 13px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">2.06</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.04</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-align: left;">Expected term, years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5.35</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6.10</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td>Volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Risk free rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.0</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.8</td> <td style="text-align: left;">%</td> </tr> </table> </div>

11215147

7324727

3890420

14786447

9548969

5237478

504349

250000 4621345 4775339 2305000 2106584

0.17

0.11

0.45

0.78

0.50

0.16

0.80

0.19

1 2 9321585

100420

125039

197339

198285

1530258

1657808

678982

399024

38101

144189

2272727

2.20

2272727

68182

2272727

3.50

2.53

4319861

1.15

7208060

9548969

2340909 3.64 3.60 3.47

5237478

4403234

5000

837328

280000

3084

3829118

1408360

3.76

4.08

2.07

3.07

3.95 129083 3.04 2.06 3.04 2.06

P6Y1M6D

P5Y4M6D

1.30

1.12

0.0180

0.020

8833333

833334

275752

5759601

74537

3568665

P3Y3M7D

P4Y7M28D

2.71

1.68

30000

P3Y

458098

144716

140397

100000 P1Y 800000 300000 8000000 100000 2000000

<div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 36%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.67in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="9" nowrap="nowrap">Three Months Ended December 31,</td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2016</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="width: 405px; text-align: left;">United States</td> <td style="width: 5px;"> </td> <td style="width: 7px; text-align: left;">$</td> <td style="width: 54px; text-align: right;">588,900</td> <td style="width: 5px; text-align: left;"> </td> <td style="width: 5px;"> </td> <td style="width: 7px; text-align: left;">$</td> <td style="width: 55px; text-align: right;">1,049,402</td> <td style="width: 5px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Europe</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">294,333</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">240,192</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: azure;"> <td style="text-align: left; padding-bottom: 2px;">Asia and other</td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">19,775</td> <td style="text-align: left; padding-bottom: 2px;"> </td> <td style="padding-bottom: 2px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">34,520</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">903,008</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,324,114</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> </div>

400000

300000

13986

900000

468000

693214

704417

630900

198591

2737588

2259707

0.0999

5000000

222290

P7Y11M27D

42335 0000744452us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2016-10-012016-12-31 2 0000744452us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2015-10-012015-12-31 3 0000744452us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2016-10-012016-12-31 0000744452us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2015-10-012016-09-30 5000000

EX-101.SCH 7 apdn-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - GEOGRAPHIC AREA INFORMATION link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - GEOGRAPHIC AREA INFORMATION (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - INVENTORIES (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - CAPITAL STOCK (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - GEOGRAPHIC AREA INFORMATION (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 apdn-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 apdn-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 apdn-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Preferred Stock [Member] Series A Preferred stock Series B Preferred Stock [Member] Series B Preferred stock Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable, net of allowance of $23,411 and $32,965 at December 31, 2016 and September 30, 2016, respectively Accounts receivable Inventory, Net Inventories Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net of accumulated depreciation of $1,363,789 at December 31, 2016 and $1,263,200 at September 30, 2016 Property plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent [Abstract] Other assets: Accounts Receivable, Net, Noncurrent Long-term accounts receivable revenue recognized Long term accounts receivables Deposits Assets, Noncurrent Deposits Deferred Offering Costs Deferred offering costs Goodwill Finite-Lived Intangible Assets, Net Amortization on intangible assets Intangible assets, net of accumulated amortization of $485,037 and $423,649 at December 31, 2016 and September 30, 2016, respectively Net Assets Total Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total Deferred revenue Deferred revenue Deferred revenue Liabilities, Current Total current liabilities Total current liabilities Accounts Payable, Noncurrent Long term accounts payable Represents the amount related to the long term accounts payable. Deferred Revenue, Noncurrent Long term deferred revenue Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2016 and September 30, 2016 Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2014 and September 30, 2013 Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, par value $0.001 per share; 500,000,000 shares authorized; 26,351,483 and 24,078,756 shares issued and outstanding as of December 31, 2016 and September 30, 2016, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated losses Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Stockholders' Equity Attributable To Parent Balance Total stockholders' equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity Allowance for Doubtful Accounts Receivable, Current Allowance on accounts receivable (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation on property, plant and equipment (in dollars) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization on intangible assets (in dollars) Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenue, Net [Abstract] Revenues: Sales Revenue, Goods, Net Product revenues Sales Revenue, Services, Net Service revenues Revenue, Net Net sales Total revenues Total revenues Cost of Revenue Cost of revenues Operating Expenses [Abstract] Operating expenses: Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Research and Development Expense Research and development Research and development expenses Research and development Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation and amortization Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) NET LOSS FROM OPERATIONS LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income (Expense), Net, Total Interest income, net Interest expense, net (Note C) Interest income (expense), net Other Nonoperating Income (Expense) Other expense, net Other (expense) income, net Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income taxes Loss before provision for income taxes Net loss before provision for income taxes Income Tax Expense (Benefit) Provision for income taxes Income taxes (benefit) Net Income (Loss) Attributable To Parent Net loss NET LOSS NET LOSS Earnings Per Share, Basic and Diluted Net Loss per share - basic and diluted Net loss per share-basic and diluted (in dollars per share) Net (loss) per share-basic and fully diluted Net loss per share-basic and diluted Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average shares outstanding- Basic and diluted (in shares) Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Stock based compensation expense Stock compensation expense Stock-based compensation expense Equity based compensation Fair value of vested warrants issued for services Common Stock Issued For Consulting Services Common stock issued for consulting services This element represents amount of common stock issued for consulting services during the period. Provision for Doubtful Accounts Provision for bad debts Increase (Decrease) In Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) In Accounts Receivable (Increase) decrease in accounts receivable Accounts receivable Increase (Decrease) in Inventories Inventories Inventories Increase (Decrease) In Prepaid Expense and Other Assets Decrease in prepaid expenses and deposits Decrease in prepaid expenses and deposits Prepaid expenses and other current assets and deposits Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities (Decrease) increase in accounts payable and accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Used In Operating Activities Operating cash flow Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows used in investing activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property, plant and equipment Payments to Acquire Intangible Assets Purchase of intangible assets Net Cash Provided By (Used In) Investing Activities, Continuing Operations Cash flows from investing activities Net cash used in investing activities Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Proceeds From Sale Of Common Stock And Warrants Net proceeds from sale of common stock and warrants The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity. Net proceeds from sale of common stock and warrants Proceeds from Warrant Exercises Proceeds from the exercise of warrants Net Cash Provided By (Used In) Financing Activities, Continuing Operations Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Interest Paid Cash paid during period for interest Income Taxes Paid Cash paid during period for income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Stock Issued Common stock issued upon cashless exercise of options and warrants Reclassification Of Deferred Offering Costs To Additional Paid In Capital Reclassification of deferred offering costs to additional paid-in capital This element represents amount of reclassification of deferred offering costs to additional paid in capital. Property Plant And Equipment Acquired Included In Accounts Payable Property, plant and equipment acquired, and included in accounts payable It represents property, plant and equipment acquired, included in accounts payable. Intangible Assets Acquired Included In Accounts Payable Intangible assets acquired, and included in accounts payable Represents value of intangible assets acquired, and included in accounts payable. Issuance Of Options To Settle Accrued Liability Issuance of options to settle accrued liability Represents amount related to Issuance of options to settle accrued liability. Accounting Policies [Abstract] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Business and Basis of Presentation SUMMARY OF ACCOUNTING POLICIES Liquidity And Management Plan [Abstract] Liquidity And Management Plan [Text Block] LIQUIDITY AND MANAGEMENT'S PLAN The entire disclosure about liquidity and management plan. Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] INVENTORIES Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Stockholders' Equity Note [Abstract] Capital Stock [Abstract] Shareholders' Equity and Share-Based Payments [Text Block] CAPITAL STOCK Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK OPTIONS AND WARRANTS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] GEOGRAPHIC AREA INFORMATION Business Description and Basis of Presentation [Text Block] Business and Basis of Presentation Inventory, Policy [Policy Text Block] Inventories Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Use of Estimates, Policy [Policy Text Block] Use of Estimates Income Tax, Policy [Policy Text Block] Income Taxes Income Taxes Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities excluded from computation of earning per share Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued liabilities Schedule Of Disclosure Transactions Of Warrants [Table Text Block] Schedule of transactions involving warrants Tabular disclosure of components of transactions of warrants. Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of transactions involving stock options issued to employees and consultants Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of fair value of options granted Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of net sales by geographic location of customers Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Stock Options Stock Options Employee options Stock options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from diluted net loss per share Revenue Recognition, Multiple-deliverable Arrangements [Table] Legal Entity [Axis] Entity [Domain] Himatsingka America Inc [Member] Himatsingka America Inc Himatsingka America Inc Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Deferred Revenue Deferred revenue Deferred revenue Deferral Revenue For Shipments Deferral revenue for shipments Represents amount of deferral revenue for shipments. Revenue Recognition, Milestone Method, Revenue Recognized Revenue for government contract awards Maximum Portion Of Cotton Tagging Fee Waived Maximum portion of cotton tagging fee waived Represents the amount related to maximum portion of cotton tagging fee waived. Revenue Recognition Short Term Accounts Receivable Short term accounts receivable It represent amount of short term accounts receivable. Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales [Member] Total Revenue Accounts Receivable [Member] Accounts Receivable Major Customers [Axis] Concentration Risk Type [Axis] Name Of Major Customer [Domain] Concentration Risk Type [Domain] One Customers Member Customer one It represents number of major customers in concentration risk. Two Customers Concentration Risk [Member] Customer two Definition :Reflects the percentage that revenues in the period from customer is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer. Three Customers Concentration Risk [Member] Customer three Represents the portion of customer is to net revenue. Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Percentage of total revenue and accounts receivable Concentration Risk Number Of Customers Number of customers It represents number of major customers in concentration risk. Working Capital Surplus Deficit Working capital It represents working capital surplus deficit. Stock Issued During Period, Value, New Issues Net proceeds from private placement Value of common stock and warrants purchased Inventory, Raw Materials, Gross Raw materials Inventory, Finished Goods, Gross Finished goods Accounts Payable, Current Accounts payable Accrued Salaries, Current Accrued salaries payable Other Accrued Liabilities, Current Other accrued expenses Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Agreement [Axis] Agreement [Axis] Information related to an agreement which represents negotiated and usually legally enforceable understanding between two or more legally competent parties. Agreement [Domain] Agreement [Domain] Information related to an agreement which represents negotiated and usually legally enforceable understanding between two or more legally competent parties. Securities Purchase Agreement [Member] Securities Purchase Agreement Represents securities purchase agreement. Sale of Stock [Axis] Sale of Stock [Domain] EX-101.PRE 11 apdn-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2016	Feb. 01, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	0000744452
Trading Symbol	apdn
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		26,351,483
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Current assets:
Cash and cash equivalents	$ 6,701,586	$ 4,479,274
Accounts receivable, net of allowance of $23,411 and $32,965 at December 31, 2016 and September 30, 2016, respectively	6,156,173	6,374,895
Inventories	323,324	297,759
Prepaid expenses and other current assets	133,230	200,006
Total current assets	13,314,313	11,351,934
Property, plant and equipment, net of accumulated depreciation of $1,363,789 at December 31, 2016 and $1,263,200 at September 30, 2016	723,790	792,499
Other assets:
Long term accounts receivables	920,000	1,535,000
Deposits	61,626	61,126
Deferred offering costs		13,986
Goodwill	285,386	285,386
Intangible assets, net of accumulated amortization of $485,037 and $423,649 at December 31, 2016 and September 30, 2016, respectively	1,464,512	1,525,900
Total Assets	16,769,627	15,565,831
Current liabilities:
Accounts payable and accrued liabilities	2,201,021	2,247,341
Deferred revenue	1,791,707	1,837,588
Total current liabilities	3,992,728	4,084,929
Long term accounts payable	127,000	215,500
Long term deferred revenue	468,000	900,000
Total liabilities	4,587,728	5,200,429
Commitments and contingencies
Stockholders' Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2016 and September 30, 2016
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 26,351,483 and 24,078,756 shares issued and outstanding as of December 31, 2016 and September 30, 2016, respectively	26,351	24,079
Additional paid in capital	239,934,320	234,158,711
Accumulated deficit	(227,778,772)	(223,817,388)
Total stockholders' equity	12,181,899	10,365,402
Total Liabilities and Stockholders' Equity	16,769,627	15,565,831
Series A Preferred stock
Stockholders' Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2016 and September 30, 2016
Series B Preferred stock
Stockholders' Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2016 and September 30, 2016

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Allowance on accounts receivable (in dollars)	$ 23,411	$ 32,965
Accumulated depreciation on property, plant and equipment (in dollars)	1,363,789	1,263,200
Accumulated amortization on intangible assets (in dollars)	$ 485,037	$ 423,649
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	26,351,483	24,078,756
Common stock, shares outstanding	26,351,483	24,078,756
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product revenues	$ 704,417	$ 693,214
Service revenues	198,591	630,900
Total revenues	903,008	1,324,114
Cost of revenues	274,832	184,268
Operating expenses:
Selling, general and administrative	3,900,917	3,169,063
Research and development	518,628	672,965
Depreciation and amortization	161,977	218,346
Total operating expenses	4,581,522	4,060,374
LOSS FROM OPERATIONS	(3,953,346)	(2,920,528)
Other income (expense):
Interest income, net	1,331	2,845
Other expense, net	(9,369)	(8,587)
Loss before provision for income taxes	(3,961,384)	(2,926,270)
Provision for income taxes
NET LOSS	$ (3,961,384)	$ (2,926,270)
Net loss per share-basic and diluted (in dollars per share)	$ (0.16)	$ (0.13)
Weighted average shares outstanding- Basic and diluted (in shares)	25,427,407	22,542,176

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (3,961,384)	$ (2,926,270)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	161,977	218,346
Stock-based compensation expense	1,458,020	396,991
Common stock issued for consulting services		58,120
Provision for bad debts	5,646	10,000
Change in operating assets and liabilities:
Accounts receivable	828,076	(4,480)
Inventories	(26,065)
Prepaid expenses and other current assets and deposits	66,776	71,896
Accounts payable and accrued liabilities	(124,053)	(320,825)
Deferred revenue	(477,881)	(224,524)
Net cash used in operating activities	(2,068,888)	(2,720,746)
Cash flows used in investing activities:
Purchase of property, plant and equipment	(42,647)	(51,795)
Purchase of intangible assets		(14,301)
Net cash used in investing activities	(42,647)	(66,096)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	4,333,847	7,853,155
Proceeds from the exercise of warrants		4,410
Net cash provided by financing activities	4,333,847	7,857,565
Net increase in cash and cash equivalents	2,222,312	5,070,723
Cash and cash equivalents at beginning of period	4,479,274	7,312,184
Cash and cash equivalents at end of period	6,701,586	12,382,907
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest
Cash paid during period for income taxes
Non-cash investing and financing activities:
Common stock issued upon cashless exercise of options and warrants		49
Reclassification of deferred offering costs to additional paid-in capital	$ 13,986
Property, plant and equipment acquired, and included in accounts payable		40,908
Intangible assets acquired, and included in accounts payable		17,841
Issuance of options to settle accrued liability		$ 42,335

XML 17 R6.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

Business and Basis of Presentation

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or market, with cost determined by using the first-in, first-out (FIFO) method.

Revenue Recognition

Use of Estimates

Income Taxes

Net Loss Per Share

For the three month periods ended December 31, 2016 and 2015, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

	2016		2015

Warrants		9,548,969		7,324,727
Stock options		5,237,478		3,890,420
		14,786,447		11,215,147

Stock-Based Compensation

Concentrations

Recent Accounting Pronouncements

XML 18 R7.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN

3 Months Ended

Dec. 31, 2016

Liquidity And Management Plan [Abstract]

LIQUIDITY AND MANAGEMENT'S PLAN

NOTE B — LIQUIDITY AND MANAGEMENT’S PLAN

XML 19 R8.htm IDEA: XBRL DOCUMENT

INVENTORIES

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

NOTE C — INVENTORIES

Inventories consist of the following:

	December 31, 2016		September 30, 2016
	(unaudited)
Raw materials	$	125,039	$	100,420
Finished goods		198,285		197,339
Total	$	323,324	$	297,759

XML 20 R9.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

3 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are as follows:

	December 31, 2016		September 30, 2016
	(unaudited)
Accounts payable	$	1,657,808	$	1,530,258
Accrued salaries payable		399,024		678,982
Other accrued expenses		144,189		38,101
Total	$	2,201,021	$	2,247,341

XML 21 R10.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK	3 Months Ended
CAPITAL STOCK	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	NOTE E — CAPITAL STOCK On November 2, 2016, the Company entered into a securities purchase agreement with an institutional investor providing for the purchase of $5 million of common stock and warrants at a combined price of $2.20 per share of common stock and warrant (the “Private Placement”). In the Private Placement, the Company sold 2,272,727 shares of its common stock and warrants to purchase 2,272,727 shares of its common stock. The warrants have the same terms as the Company's existing publicly traded warrants (APDNW) with an exercise price of $3.50 per share and an expiration date of November 20, 2019. The offering closed on November 7, 2016. The Company agreed to file a registration statement providing for the resale of these securities on Form S-3 by December 7, 2016. On December 6, 2016, the Company filed the Form S-3, which was declared effective by the SEC on December 13, 2016. Upon effectiveness of the registration statement, the common stock and warrants issued in the Private Placement became freely tradeable on The NASDAQ Capital Market under the symbols "APDN" and "APDNW", respectively. The aggregate gross proceeds to the Company from the Private Placement were $5 million before deducting the placement agents' fee and other offering expenses. As a result of the placement agents’ fee and other offering expenses attributable to the Private Placement, the net proceeds were $4,319,861. In connection with the closing of this Private Placement, as partial compensation, on November 7, 2016, the Company granted warrants to purchase an aggregate of 68,182 shares of its common stock to the Company's placement agents, Maxim Group LLC and Imperial Capital LLC (the “Placement Agent Warrants”) at an exercise price of $2.53 (115% of the public offering price), subject to adjustment as set forth therein (including for stock dividends and splits and certain other distributions and “Fundamental Transactions,” as defined therein). The Placement Agent Warrants will be exercisable beginning six months following the closing date of the Private Placement and terminate at 5:00 P.M. (Eastern Standard Time) on November 7, 2021. In addition, the Placement Agent Warrants provide for cashless exercise, which the Placement Agents may elect if there is no effective registration statement registering the resale of the shares issuable upon exercise of the Placement Agent Warrants. The number of shares of common stock that may be acquired by the Placement Agents upon any exercise of the Placement Agent Warrants (or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise, the total number of shares of common stock then beneficially owned by the Placement Agent and its Affiliates (as defined therein) and any other Persons whose beneficial ownership of common stock would be aggregated with the Placement Agent pursuant to the Exchange Act, does not exceed 9.99% of the total number of issued and outstanding shares of common stock.

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE F — STOCK OPTIONS AND WARRANTS

Warrants

Transactions involving warrants are summarized as follows:

	Number of Shares		Weighted Average Exercise Price Per Share
Balance at October 1, 2016		7,208,060	$	3.64
Granted		2,340,909		3.47
Exercised		-		-
Cancelled or expired		-		-
Balance at December 31, 2016		9,548,969	$	3.60

Stock Options

Transactions involving stock options issued to employees and consultants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2016		4,403,234		$	4.08
Granted		837,328			2.07
Exercised		-			-
Cancelled or expired		(3,084	)		(3.07	)
Outstanding at December 31, 2016		5,237,478		$	3.76
Vested at December 31, 2016		3,829,118		$	3.95		$	222,290		4.66
Non-vested at December 31, 2016		1,408,360					$	129,083		7.99

	Three Months Ended December 31, 2016			Three Months Ended December 31, 2015
Stock price	$	2.06		$	3.04
Exercise price	$	2.06		$	3.04
Expected term, years		5.35			6.10
Dividend yield		-	%		-	%
Volatility		112	%		130	%
Risk free rate		2.0	%		1.8	%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE G — COMMITMENTS AND CONTINGENCIES Operating Leases The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expired on May 31, 2016, with the option to extend the lease for up to two additional three-year periods. The Company has exercised its option to extend the lease for one additional three-year period, ending May 31, 2019. The base rent during the additional three-year period is $458,098 per annum. Total rent expense for the three months ended December 31, 2016 and 2015 was $140,397 and $144,716, respectively. Employment Agreement The Company has an employment agreement with Dr. James Hayward, its Chief Executive Officer. On July 28, 2016, a new employment agreement was entered into with the Chief Executive Officer effective July 1, 2016. The initial term is from July 1, 2016 through June 30, 2017, with automatic one-year renewal periods. The terms of the agreement are substantially the same as his original employment agreement, except the cash incentive bonus was modified. Under the new agreement, Dr. Hayward will be eligible for a special cash incentive bonus of up to $800,000, $300,000 of which will be payable if and when annual revenue reaches $8 million and $100,000 of which would be payable for each $2 million of annual revenue in excess of $8 million. Dr Hayward's annual salary is $400,000. Effective May 7, 2016, the Chief Executive Officer's annual salary was voluntarily reduced by $100,000. Accordingly, his current annual base salary as of December 31, 2016 is $300,000. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

XML 24 R13.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

GEOGRAPHIC AREA INFORMATION

NOTE H– GEOGRAPHIC AREA INFORMATION

Net revenues by geographic location of customers are as follows:

Three Months Ended December 31,
	2016		2015
United States	$	588,900	$	1,049,402
Europe		294,333		240,192
Asia and other		19,775		34,520
Total	$	903,008	$	1,324,114

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Policies)

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Business and Basis of Presentation

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or market, with cost determined by using the first-in, first-out (FIFO) method.

For the three month periods ended December 31, 2016 and 2015, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

	2016		2015

Warrants		9,548,969		7,324,727
Stock options		5,237,478		3,890,420
		14,786,447		11,215,147

Stock-Based Compensation

Concentrations

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration they expect to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of ASU 2014-09 and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. We expect to identify similar performance obligations under ASC 606 as compared with deliverables and separate units of account previously identified. As a result, we expect the timing of our revenue to remain the same.

XML 26 R15.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of anti-dilutive securities excluded from computation of earning per share

	2016		2015

Warrants		9,548,969		7,324,727
Stock options		5,237,478		3,890,420
		14,786,447		11,215,147

XML 27 R16.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of inventories

	December 31, 2016		September 30, 2016
	(unaudited)
Raw materials	$	125,039	$	100,420
Finished goods		198,285		197,339
Total	$	323,324	$	297,759

XML 28 R17.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

3 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

	December 31, 2016		September 30, 2016
	(unaudited)
Accounts payable	$	1,657,808	$	1,530,258
Accrued salaries payable		399,024		678,982
Other accrued expenses		144,189		38,101
Total	$	2,201,021	$	2,247,341

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of transactions involving warrants

	Number of Shares		Weighted Average Exercise Price Per Share
Balance at October 1, 2016		7,208,060	$	3.64
Granted		2,340,909		3.47
Exercised		-		-
Cancelled or expired		-		-
Balance at December 31, 2016		9,548,969	$	3.60

Schedule of summary of transactions involving stock options issued to employees and consultants

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2016		4,403,234		$	4.08
Granted		837,328			2.07
Exercised		-			-
Cancelled or expired		(3,084	)		(3.07	)
Outstanding at December 31, 2016		5,237,478		$	3.76
Vested at December 31, 2016		3,829,118		$	3.95		$	222,290		4.66
Non-vested at December 31, 2016		1,408,360					$	129,083		7.99

Schedule of fair value of options granted

	Three Months Ended December 31, 2016			Three Months Ended December 31, 2015
Stock price	$	2.06		$	3.04
Exercise price	$	2.06		$	3.04
Expected term, years		5.35			6.10
Dividend yield		-	%		-	%
Volatility		112	%		130	%
Risk free rate		2.0	%		1.8	%

XML 30 R19.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION (Tables)

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Schedule of net sales by geographic location of customers

Three Months Ended December 31,
	2016		2015
United States	$	588,900	$	1,049,402
Europe		294,333		240,192
Asia and other		19,775		34,520
Total	$	903,008	$	1,324,114

XML 31 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) - shares	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	14,786,447	11,215,147
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	9,548,969	7,324,727
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	5,237,478	3,890,420

XML 32 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 29, 2016	Dec. 31, 2015	Dec. 31, 2016	Sep. 30, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenue			$ 2,259,707	$ 2,737,588
Revenue for government contract awards		$ 504,349
Short term accounts receivable			4,775,339	4,621,345
Long-term accounts receivable revenue recognized			920,000	1,535,000
Deferral revenue for shipments			$ 2,106,584	$ 2,305,000
Himatsingka America Inc
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Maximum portion of cotton tagging fee waived	$ 250,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) - Customer Concentration Risk - Customer	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Total Revenue
Concentration Risk [Line Items]
Number of customers	2	3
Total Revenue \| Customer one
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	19.00%	45.00%
Total Revenue \| Customer two
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	50.00%	17.00%
Total Revenue \| Customer three
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable		11.00%
Accounts Receivable
Concentration Risk [Line Items]
Number of customers	2		1
Accounts Receivable \| Customer one
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	80.00%		78.00%
Accounts Receivable \| Customer two
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	16.00%

XML 34 R23.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) - USD ($)		3 Months Ended
	Nov. 07, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Liquidity And Management Plan [Abstract]
Accumulated deficit		$ (227,778,772)		$ (223,817,388)
Net loss		(3,961,384)	$ (2,926,270)
Operating cash flow		(2,068,888)	(2,720,746)
Working capital		9,321,585
Cash and cash equivalents		$ 6,701,586	$ 12,382,907	$ 4,479,274	$ 7,312,184
Gross proceeds from common stock and warrants upon closure of private placement	$ 5,000,000
Net proceeds after deducting placement agent fees and offering expenses	$ 4,319,861

XML 35 R24.htm IDEA: XBRL DOCUMENT

INVENTORIES (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 125,039	$ 100,420
Finished goods	198,285	197,339
Total	$ 323,324	$ 297,759

XML 36 R25.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 1,657,808	$ 1,530,258
Accrued salaries payable	399,024	678,982
Other accrued expenses	144,189	38,101
Total	$ 2,201,021	$ 2,247,341

XML 37 R26.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK (Detail Textuals) - USD ($)	Nov. 07, 2016	Nov. 02, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from the Private Placement	$ 5,000,000
Net proceeds after deducting placement agent fees and offering expenses	$ 4,319,861
Securities Purchase Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of common stock and warrants purchased		$ 5,000,000
Share price (in dollars per share)		$ 2.20
Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued		2,272,727
Number of common stock called by warrants	68,182	2,272,727	2,272,727
Exercise price of warrants (in dollars per share)	$ 2.53	$ 3.50
Exercise price percentage of public offering price	115.00%
Maximum total number issued and outstanding shares of common stock	9.99%

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details)	3 Months Ended
	Dec. 31, 2016 $ / shares shares
Number of Shares
Balance at October 1, 2016 \| shares	7,208,060
Granted \| shares	2,340,909
Exercised \| shares
Cancelled or expired \| shares
Balance at December 31, 2016 \| shares	9,548,969
Weighted Average Exercise Price Per Share
Balance at October 1, 2016 \| $ / shares	$ 3.64
Granted \| $ / shares	3.47
Exercised \| $ / shares
Cancelled or expired \| $ / shares
Balance at December 31, 2016 \| $ / shares	$ 3.60

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) - Stock Options - 2005 Incentive Stock Plan	3 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Number of Shares
Outstanding at October 1, 2016	4,403,234
Granted	837,328
Exercised
Cancelled or expired	(3,084)
Outstanding at December 31, 2016	5,237,478
Vested at December 31, 2016	3,829,118
Non-vested at December 31, 2016	1,408,360
Weighted Average Exercise Price Per Share
Outstanding at October 1, 2016 \| $ / shares	$ 4.08
Granted \| $ / shares	2.07
Exercised \| $ / shares
Cancelled or expired \| $ / shares	(3.07)
Outstanding at December 31, 2016 \| $ / shares	3.76
Vested at December 31, 2016 \| $ / shares	$ 3.95
Aggregate Intrinsic Value, Vested at December 31, 2016 \| $	$ 222,290
Aggregate Intrinsic Value, Non-vested at December 31, 2016 \| $	$ 129,083
Weighted Average Contractual Life (years) vested at December 31, 2016	4 years 7 months 28 days
Weighted Average Contractual Life (years), Non-vested at December 31, 2016	7 years 11 months 27 days

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) - $ / shares	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock price	$ 2.06	$ 3.04
Exercise price	$ 2.06	$ 3.04
Expected term, years	5 years 4 months 6 days	6 years 1 month 6 days
Dividend yield
Volatility	112.00%	130.00%
Risk free rate	2.00%	1.80%

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Detail Textuals) - shares	3 Months Ended
STOCK OPTIONS AND WARRANTS (Detail Textuals) - shares	Dec. 31, 2016	Nov. 07, 2016	Nov. 02, 2016
Private placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock called by warrants	2,272,727	68,182	2,272,727
Stock Options \| 2005 Incentive Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option	8,833,333
Number of common stock shares that can be covered by awards made to any participant per period	833,334
Number of shares issued	275,752
Options to purchase shares under the 2005 Incentive Stock Plan	5,759,601

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Detail Textuals 1) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,458,020	$ 396,991
Stock option modifications expense	74,537
Unrecorded compensation cost related to non-vested awards	$ 3,568,665
Weighted average period for non-vested awards	3 years 3 months 7 days
Weighted average grant date fair value for options granted	$ 1.68	$ 2.71
Stock Options \| Employees, non-employee board of director members and members of the strategic advisory board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	837,328
Stock Options \| Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	280,000
Performance based options to consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	5,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Detail Textuals)	1 Months Ended		3 Months Ended
COMMITMENTS AND CONTINGENCIES (Detail Textuals)	Jul. 28, 2016 USD ($)	Jun. 15, 2013 USD ($) ft²	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	May 07, 2016 USD ($)
Commitments And Contingencies [Line Items]
Area of property under operating lease \| ft²		30,000
Extended operating lease for two additional period		3 years
Base rent during initial lease term per annum		$ 458,098
Total rent expense			$ 140,397	$ 144,716
Employment Agreement \| Dr. James Hayward - Chief Executive Officer
Commitments And Contingencies [Line Items]
Annual base salary			$ 300,000
Reduction in annual salary					$ 100,000
New Employment Agreement \| Dr. James Hayward - Chief Executive Officer
Commitments And Contingencies [Line Items]
Agreement renewal period	1 year
Special cash incentive bonus	$ 800,000
Special cash incentive bonus on completing threshold annual revenue	300,000
Threshold annual revenue	8,000,000
Special cash incentive bonus on completing threshold annual revenue in excess of first threshold revenue	100,000
Threshold annual revenue in excess of first threshold	2,000,000
Annual base salary	$ 400,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION (Details) - USD ($)	3 Months Ended
GEOGRAPHIC AREA INFORMATION (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net sales	$ 903,008	$ 1,324,114
United States
Segment Reporting Information [Line Items]
Net sales	588,900	1,049,402
Europe
Segment Reporting Information [Line Items]
Net sales	294,333	240,192
Asia and other
Segment Reporting Information [Line Items]
Net sales	$ 19,775	$ 34,520

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 53 183 1 false 24 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.adnas.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES SUMMARY OF ACCOUNTING POLICIES Notes 6 false false R7.htm 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN Sheet http://www.adnas.com/role/LiquidityAndManagementSPlan LIQUIDITY AND MANAGEMENT'S PLAN Notes 7 false false R8.htm 008 - Disclosure - INVENTORIES Sheet http://www.adnas.com/role/Inventories INVENTORIES Notes 8 false false R9.htm 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 9 false false R10.htm 010 - Disclosure - CAPITAL STOCK Sheet http://www.adnas.com/role/CAPITALSTOCK CAPITAL STOCK Notes 10 false false R11.htm 011 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS STOCK OPTIONS AND WARRANTS Notes 11 false false R12.htm 012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 013 - Disclosure - GEOGRAPHIC AREA INFORMATION Sheet http://www.adnas.com/role/GeographicAreaInformation GEOGRAPHIC AREA INFORMATION Notes 13 false false R14.htm 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 015 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables SUMMARY OF ACCOUNTING POLICIES (Tables) Tables http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES 15 false false R16.htm 016 - Disclosure - INVENTORIES (Tables) Sheet http://www.adnas.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.adnas.com/role/Inventories 16 false false R17.htm 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES 17 false false R18.htm 018 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS 18 false false R19.htm 019 - Disclosure - GEOGRAPHIC AREA INFORMATION (Tables) Sheet http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONTables GEOGRAPHIC AREA INFORMATION (Tables) Tables http://www.adnas.com/role/GeographicAreaInformation 19 false false R20.htm 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesSummaryOfPotentialStockIssuancesUnderVariousOptionsAndWarrantsDetails SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Details 20 false false R21.htm 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesDetailTextuals SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 21 false false R22.htm 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailTextuals1 SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 22 false false R23.htm 023 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Sheet http://www.adnas.com/role/LiquidityAndManagementSPlanDetailTextuals LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Details http://www.adnas.com/role/LiquidityAndManagementSPlan 23 false false R24.htm 024 - Disclosure - INVENTORIES (Details) Sheet http://www.adnas.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.adnas.com/role/INVENTORIESTables 24 false false R25.htm 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESSummaryOfAccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Details 25 false false R26.htm 026 - Disclosure - CAPITAL STOCK (Detail Textuals) Sheet http://www.adnas.com/role/CAPITALSTOCKDetails6 CAPITAL STOCK (Detail Textuals) Details http://www.adnas.com/role/CAPITALSTOCK 26 false false R27.htm 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingWarrantsDetails STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Details 27 false false R28.htm 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTransactionsInvolvingStockOptionsIssuedToEmployeesAndConsultantsDetails1 STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) Details 28 false false R29.htm 029 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsSummaryOfValueOfOptionsGrantedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Details 29 false false R30.htm 030 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals STOCK OPTIONS AND WARRANTS (Detail Textuals) Details http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables 30 false false R31.htm 031 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals 1) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals1 STOCK OPTIONS AND WARRANTS (Detail Textuals 1) Details http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables 31 false false R32.htm 032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIESDetailTextuals COMMITMENTS AND CONTINGENCIES (Detail Textuals) Details http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES 32 false false R33.htm 033 - Disclosure - GEOGRAPHIC AREA INFORMATION (Details) Sheet http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONDetails GEOGRAPHIC AREA INFORMATION (Details) Details http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONTables 33 false false All Reports Book All Reports apdn-20161231.xml apdn-20161231.xsd apdn-20161231_cal.xml apdn-20161231_def.xml apdn-20161231_lab.xml apdn-20161231_pre.xml true true ZIP 51 0001571049-17-001169-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-17-001169-xbrl.zip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
53=QI.PZW:QPAC?.JS M>(H4V.XM(SM9J1\!:_:D/C5LY.5.X(FG@$W?,@+)%N4AAE;,SLTYK^F4^2@1 M=< M'O5Z&+ 9:#3?S5&\^3F?4N^99K *PNQM=VB.32QRM.<3 M [FMY?G-F?:DD$'O3RLZV2,_JK/UZ'JB_ZL@UPE7<'OKGD.^UHSUACW["G 5G;@<>?X7-I@/S=A:4K Z@=<9U,>2EC MV)\^Y=.K8;,81XTJ-2$;BC[,>"HZPLC0 SF^2P]N67#U%1N,_RLUFA\(7;[H M#&4B9'G;G BK;3;H1"K'Y[7K].+\O'>8(-,?!R\V-D=S"H'-98XU)I0+/JN= M%Q70XDT&=;ZR4:I4OP" KRIQ=(ZNBS%@;4Z7ICMD!688$1KW7%O0_]VCL"Y& M#+#_SM(W9]8>KJ+5YFE.638VN8Q=HN 54);9-E2\VO5F8KP]T9F#8&;7D.A] M\ODFUK+B 6E%',P.W#UVL+=$UH/K6E)B/2 #B8O)]#DI1OVOSK+BTK/:290(M=&XK/I=C;D[Z<>$C0Q()Q M7"2M6.^VHV1JV 9AMC09P680 *]W106;C:0=Z]W(7R)R/ GF2UA,"+PF%I)T M+J)VQ,/(K('*,[>H%>#;5E5,YSGPJG,BG'S[U-/&@YGV&!;]W.Y\OIR\Z!0S MQ"U=F_+08X9>?S-T?9FCOI@0M*I,;E$TCU<53;Z@3,EW0)>7RA,>9VA6B?_, M0L*U!4&153'[TL7Q0V=3?*4"66387]-8P>YEY F,>[TBZS%(9_L11T5NR.* [EQ#24Y[!]@SAR$!HQ9ES&KQXV,(&V;"+E'2& M"=UUXMMH7!K@N]\USI,RT!M^3SP!*+KLD"CEG7NO+9\8NG:(2' <6><38!\.5Q.4%E"YD+J+;9G?=?(PJ'/TK$+V%/PE53:H!Z%M&%AJ",RP8NE']_\VQ_Y>X9MLUL.<9R+>L=V#P]M:I5 M!;RI[!K"N2E?_QT1$WLH'&Z['W?8A?>JB[2G=V#S!IU>T60X4N_5AM:%F.M= M8)]6'4I4$5]J#$8_]9[I)9_#+VD.Q];R[6A+7 '9)DG(VW35\E*]"^S JWW7 M5AO;8GW^>GY3X[9.R8Q% M5=N$6(HE.X-#]1:'RY7!\[@R6+\&GN):X8\-K$_"\(_"[GH)-B0\'][ >77M M5PH]_A$HYGY_8R*<(7;:,4%A\I">Z_G>T0HE$Y9?KF&EP#5>4B7AT3:<%2>N M;=^[A.DZ;U)0:P4XH*PTT[,&N3('6A%[D8DZL:RJ'OX3I)#):-2%J7"#W(."2AM0%6( => ^YD>*B1@] S'1"RX943"K7(I?3AN#*I,#:!B M9#,!^N1Q3KL&H/HW9[)M2%3*J>7X<0+_#DL5,!K/!J/A5!O>?=,F$VTXFV;Z M=Y*^H,@].W/[J[7M;J(XE1[]/K#]A OHY$7KV^ #NB0O:/K1M$W)#2I*4Q-" MV43USP4:=?!<>],A\. V6\C%V;3G@V.Q1+[L>F7^7> :7@>I('SCS2CW( MFZU]\4XDL4O)O6;,I0'.@6<067 >JARZVKV!$^4!"2_4R##6.'%F MO$WOP-K%FS9Q-4W=![[;&NUQ<_2&87F\]BL85'3S@891O#ID^N^7.ODI(65LL M2+@P#AR?8,?#9EC4JL:%I'B?&CFP3F S+B%EX+CZHFM&#D-V+J1Q1 M-MS:AOE]:BYI*U[T,SO_T!^>7 O9W["_3#%0\[Q@%;5SJ62"BF:Q$LUAX0%T M]N8*)YCXH9;EALH$"'S3L>KUYM[ )!R0B:%T8'S(DWU=+P7.*%6?+M7(L!9Y MLHOL+;.YM-U?UG5FR'TI<)ZJVA+FUH< MMNU1\@GVOM\3Q+P4B.J4?TH5SWHW<&:U1B@XAV^566@RU!O,1).177)K5YG1 M-P3&Q;QR21)^21)^21)^21+.49!+DO!+DG"A/E0==WQ)$G[ R$N2\#PN5*43 MA9SEETSAM:T\ETSAETSAETSAETSA@MU<\.)A"QMD,S7"J8A!S9E#N31_@KS> M NB5N:> ]O5[0&QDC.:)$G+YN_1<8NC\V2+!<60M@ZG9N^DQP:^&C^C49H;# M(G+J!WS>^GHQSI<$;O&P1,Z-Z(41"4E:\]!&S,+ONXR MGB$S(-C'R.L9K&3O[2;V0&P?%*EBR98;F\SY4$FR-; "WK3 0%"8Q8<9^;3 M7[H$_R'.)E[UNQJ;OUE&/VOA5HNB'HNPYLEXQZM@=JQ#)<^Y-'/D8\B6H/U)D_/^L]C55C\RZ?0%TSF5591.(97:K+C]CJ7$*V+B%;EY"M2\C6)63K$K)U"=FZ MA&Q=0K8N(5LG]SXB,G?)RG!,%&W0\]V/V130@5PG50H^#]IA\IQAGRWM \=B M]R/I825G9Y+Y/'#,UPEV*#S8#8_Q.X+%\KN$VWUVB%WB]141=V0\S:S*!4H>B"N5XM>\M\&'HU7C195K*)B?E4V@YY= M:)2R[K4AB$Y1?9*Q<:5GK;/3 G6,:O%DVMANJT(20:.24("PTZVQ#PU=;VI TA M42?:U4KQLK)Z].U< R).WKMD^Q5[3I1C]K0=.6E S\EF;1[4>C+FUSS23Q0[ MV!L]/0UF3_WA;*H-[WJCX6PP?.@/>X/^%#:[&^7="OM1))=CL2((F++/,3'R M]O%@$I&!2NU4D1I?\$)>P)X4'7 0GBH?L[P2$A";'>12C=<:QGXB+2$53W2% M=I$SD>C)/-&P=@JN.*OQ1#<]FJVWQ&BN[%X44 %'M!607[8BB"&>9X$4;4%0 MN#'CS-;'#P&%FA6,7M%A+$01=U4F MN":# "ATBL=F;E!,=M?/B'PW6_4=D>-S#?"XAE!]2 M31Q9*YH,LG8$E#TBST.(@6)EQ!/A48> O0ERT!NWUFJ)UJ"<=V64I"1@K(A]6. (%C3?5922/'0T,D M,CD+Z:#\D%6,Z5Q@]?K)*]F>W2&3L-X/'&WE!HX_FD\-VR ;WACF/:]W8<)Y M2X]>$:#=NEU#<>E*C /;U8*;_$?PM-Z%<:"4WW%QX<3B^NF\I+7-935=(Y,N M##W#6^YR:-^Z3L ]_>31Z=WS//GD2E &6"S+K^O>2>?'#@[ M<4$=BFL;X0.G_VXBEESV'A//WSU4W\CGO5'O-O1(52]+=JIW9J?J:M1)E1_- M.W\5A+D3>\./X9$3V9.\E93UN-X%=$Z5/71S\.RDV\B%^WIM,D,LV41RW?XC M+=+MU_KS-$-V^Q^A4^.).'XHI(,^MR/?3,#MDQ<7I_?0KGZ> MQ\##!MUMC_RE("Z7\R1TVCAYF? !0/O1Z]F5)];V1YFD/1+DP!G?JMW'R.%M M>') 5N?/VYH_Q([XU)/0A4DEI<.1[1&6NG*_9A[^KUFG6'YU^H__!U!+ 0(4 M Q0 ( 'F!24I53Z;A'W@ %&8! 1 " 0 !A<&1N M+3(P,38Q,C,Q+GAM;%!+ 0(4 Q0 ( 'F!24H=[@O#DPX *Q] 1 M " 4YX !A<&1N+3(P,38Q,C,Q+GAS9%!+ 0(4 Q0 ( 'F! M24KS%*U:WP@ (QQ 5 " 1"' !A<&1N+3(P,38Q,C,Q M7V-A;"YX;6Q02P$"% ,4 " !Y@4E*4[FF:0\8 !MD@$ %0 M @ $BD 87!D;BTR,#$V,3(S,5]D968N>&UL4$L! A0#% @ >8%) M2O?7@R $3@ DJL$ !4 ( !9*@ &%P9&XM,C Q-C$R,S%? M;&%B+GAM;%!+ 0(4 Q0 ( 'F!24I85/MG*2H )+: @ 5 M " 9OV !A<&1N+3(P,38Q,C,Q7W!R92YX;6Q02P4& 8 !@"* 0 &]R ! end